Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Sanofi rated Strong BUY with 5.5%+ dividend and 16-20% returns forecast amid strong pipeline and turnaround.

Analyst Insights
11 May 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Sanofi (SNY) is rated a Strong BUY due to its robust drug pipeline, strong free cash flow, and a promising turnaround under new leadership. The company offers a dividend yield above 5.5% and is undervalued based on its multiples, with projected annualized total returns of 16–20% over the next five years. Recent product launches contributed 14% of Q1 revenue, supported by 80 pipeline products and 23 in mid-to-late stage development, indicating strong future growth potential. Sanofi's strong profitability, solid balance sheet, and focus on rare diseases and acquisitions help mitigate risks from patent expirations and competition.

More News (SNY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App